Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy adult male (18 -70 yrs)
Body weight must be ≥ 50 kg and < 120 kg, with a body mass index (BMI) >18 but < 35.
Laboratory parameters values within the normal range
Contraindication or hypersensitivity to receiving nilotinib
Smokers or those who use of tobacco products or products containing nicotine
A past medical history of clinically significant Electrocardiogram abnormalities or a history/family history of long QT-interval syndrome.
History of fainting spells.
Other protocol-defined inclusion/exclusion criteria may apply.